Scientists at the Centre for Cancer Immunology alongside Cancer Research UK and Touchlight Genetics, a London based biotechnology company, have announced a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
Copy and paste this URL into your WordPress site to embed
